Selecting the best pharmacologic therapy for a patient with type 2 diabetes mellitus
(DM) requires choosing between various oral agents, insulins, and combinations of
oral agents and insulins. As more oral agents and types of insulins have become available
over the past decade, the number of options for single-drug and multidrug therapy
has increased progressively. The decision process must factor in the patient’s disease
duration, current degree of control, responses to previous pharmacologic regimens,
and likelihood of adherence to therapy. The authors of the articles in this supplement
to The American Journal of Medicine provide insight into developing a rational approach to selecting and combining oral
agents, transitioning from oral therapy to insulin therapy, intensifying insulin therapy,
and improving adherence to pharmacologic therapy.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research.CMAJ. 2004; 171: 735-740
- Gut-derived incretin hormones and new therapeutic approaches.Diabetes Care. 2004; 27: 2554-2559
Klonoff DC. Continuous glucose monitoring: roadmap to 21st century diabetes therapy. Diabetes Care. In press.
- Waiting to inhale.Curr Diab Rep. 2004; 4: 335-341
Article info
Identification
Copyright
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
